(Q24563115)

Leon W M M

Terstappen

1 reference

19 October 2023

17

Dorothee Herlyn

Dorothee

Herlyn

1 reference

19 October 2023

Songdong Meng

1

Songdong

Meng

1 reference

19 October 2023

Debasish Tripathy

2

Debasish

Tripathy

1 reference

19 October 2023

Sanjay Shete

3

Sanjay

Shete

1 reference

19 October 2023

Raheela Ashfaq

4

Raheela

Ashfaq

1 reference

19 October 2023

Barbara Haley

5

Barbara

Haley

1 reference

19 October 2023

Steve Perkins

6

Steve

Perkins

1 reference

19 October 2023

Peter Beitsch

7

Peter

Beitsch

1 reference

19 October 2023

Amanullah Khan

8

Amanullah

Khan

1 reference

19 October 2023

David Euhus

9

David

Euhus

1 reference

19 October 2023

Cynthia Osborne

10

Cynthia

Osborne

1 reference

19 October 2023

Eugene Frenkel

11

Eugene

Frenkel

1 reference

19 October 2023

Susan Hoover

12

Susan

Hoover

1 reference

19 October 2023

Marilyn Leitch

13

Marilyn

Leitch

1 reference

19 October 2023

Edward Clifford

14

Edward

Clifford

1 reference

19 October 2023

Larry Morrison

16

Larry

Morrison

1 reference

19 October 2023

Timothy Fleming

19

Timothy

Fleming

1 reference

19 October 2023

Thomas Tucker

21

Thomas

Tucker

1 reference

19 October 2023

Jianqiang Wang

23

Jianqiang

Wang

1 reference

19 October 2023

Nancy Lane

22

Nancy

Proceedings of the National Academy of Sciences of the United States of America

Lane

1 reference

19 October 2023

language of work or name

English

0 references

publication date

22 June 2004

0 references

published in

0 references

volume

101

0 references

page(s)

9393-8

0 references

issue

25

0 references

cites work

Detection and characterization of carcinoma cells in the blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Targeted therapy for cancer: the HER-2/neu and Herceptin story.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=438987

Efficient selection of human tumor growth-inhibiting monoclonal antibodies

28 November 2018

1 reference

12 December 2020

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer

1 reference

12 December 2020

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report

1 reference

12 December 2020

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues

1 reference

12 December 2020

Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour

1 reference

12 December 2020

The mutation rate and cancer

1 reference

12 December 2020

C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.0402993101

1 reference

release_deueyvmob5bqtgrvxbpymorshi

0 references

0 references

1588807

1 reference

1 reference

1 reference